Maximizing the In Vivo Efficiency of Gene Transfer by Means of Nonviral Polymeric Gene Delivery Vehicles

2002 ◽  
Vol 91 (1) ◽  
pp. 67-76 ◽  
Author(s):  
Ales Prokop ◽  
Evgenii Kozlov ◽  
William Moore ◽  
Jeffrey M. Davidson
2018 ◽  
Vol 2 (4) ◽  
pp. 371-386 ◽  
Author(s):  
Feng Yin ◽  
Tommy Anderson ◽  
Nishtha Panwar ◽  
Kang Zhang ◽  
Swee Chuan Tjin ◽  
...  

2019 ◽  
Vol 7 (3) ◽  
pp. 384-392 ◽  
Author(s):  
Huajie Zhu ◽  
Jinxia An ◽  
Chengcai Pang ◽  
Shuai Chen ◽  
Wei Li ◽  
...  

Crucial light-controlled-ROS and pH-stimulus-responsive functionalities are tailored into a triblock copolymer for manufacture of gene delivery vehicles.


1997 ◽  
Vol 134 (1-2) ◽  
pp. 41
Author(s):  
M. Laitinen ◽  
T. Pakkanen ◽  
J.S. Luoma ◽  
P. Lehtolainen ◽  
H. Viita ◽  
...  

1995 ◽  
Vol 18 (1) ◽  
pp. 69-69
Author(s):  
Gail M. Seigel

AbstractGene replacement therapy holds great promise in the treatment of many genetic CNS disorders. This commentary discusses the feasibility of gene replacement therapy in the unique context of the retina, with regard to: (1) the genetics of retinal neoplasia and degeneration, (2) available gene transfer technology, and (3) potential gene delivery vehicles.


2015 ◽  
Vol 112 (22) ◽  
pp. E2947-E2956 ◽  
Author(s):  
Makoto Matsuyama ◽  
Yohei Ohashi ◽  
Tadashi Tsubota ◽  
Masae Yaguchi ◽  
Shigeki Kato ◽  
...  

Pathway-specific gene delivery is requisite for understanding complex neuronal systems in which neurons that project to different target regions are locally intermingled. However, conventional genetic tools cannot achieve simultaneous, independent gene delivery into multiple target cells with high efficiency and low cross-reactivity. In this study, we systematically screened all receptor–envelope pairs resulting from the combination of four avian sarcoma leukosis virus (ASLV) envelopes (EnvA, EnvB, EnvC, and EnvE) and five engineered avian-derived receptors (TVA950, TVBS3, TVC, TVBT, and DR-46TVB) in vitro. Four of the 20 pairs exhibited both high infection rates (TVA–EnvA, 99.6%; TVBS3–EnvB, 97.7%; TVC–EnvC, 98.2%; and DR-46TVB–EnvE, 98.8%) and low cross-reactivity (<2.5%). Next, we tested these four receptor–envelope pairs in vivo in a pathway-specific gene-transfer method. Neurons projecting into a limited somatosensory area were labeled with each receptor by retrograde gene transfer. Three of the four pairs exhibited selective transduction into thalamocortical neurons expressing the paired receptor (>98%), with no observed cross-reaction. Finally, by expressing three receptor types in a single animal, we achieved pathway-specific, differential fluorescent labeling of three thalamic neuronal populations, each projecting into different somatosensory areas. Thus, we identified three orthogonal pairs from the list of ASLV subgroups and established a new vector system that provides a simultaneous, independent, and highly specific genetic tool for transferring genes into multiple target cells in vivo. Our approach is broadly applicable to pathway-specific labeling and functional analysis of diverse neuronal systems.


2020 ◽  
Vol 6 (31) ◽  
pp. eabc2148
Author(s):  
Yuting Wen ◽  
Hongzhen Bai ◽  
Jingling Zhu ◽  
Xia Song ◽  
Guping Tang ◽  
...  

It requires multistep synthesis and conjugation processes to incorporate multifunctionalities into a polyplex gene vehicle to overcome numerous hurdles during gene delivery. Here, we describe a supramolecular platform to precisely control, screen, and optimize molecular architectures of siRNA targeted delivery vehicles, which is based on rationally designed host-guest complexation between a β-cyclodextrin–based cationic host polymer and a library of guest polymers with various PEG shape and size, and various density of ligands. The host polymer is responsible to load/unload siRNA, while the guest polymer is responsible to shield the vehicles from nonspecific cellular uptake, to prolong their circulation time, and to target tumor cells. A series of precisely controlled molecular architectures through a simple assembly process allow for a rapid optimization of siRNA delivery vehicles in vitro and in vivo for therapeutic siRNA-Bcl2 delivery and tumor therapy, indicating the platform is a powerful screening tool for targeted gene delivery vehicles.


Sign in / Sign up

Export Citation Format

Share Document